Halucenex Life Sciences

Halucenex is a clinical stage psychedelic drug development company that operates a 6,000 square foot Canadian medical facility, with 6 treatment rooms and a secure laboratory dedicated to performing psychedelic-assisted psychotherapy and clinical research.

Halucenex has a Health Canada Controlled Drug and Substances Dealer’s License for following activities: possession, production, assembly, sale/provision, sending, transportation and delivery, related to the following psychedelic compounds:

GHB, Harmaline, Ketamine, LSD, Mescaline, DMT, N METHYL 3,4 METHYLENEDIOXYAMPHETAMINE, Phencyclidine, Psilocin, Psilocybin, Salvia Divinorum , Salvinorin A. Halucenex began a Phase 2 Clinical trial in Q4 2022 to test the effectiveness of treating treatment-resistant post traumatic stress disorder with synthetic psilocybin.